TROG 20.03 - AVATAR - TROG Cancer Research

By w.paterson
21 June, 2021
0 Comments

A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer

Primary Sponsor

Victorian Comprehensive Cancer Centre (VCCC)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

Final Accrual

Closing Date of Accrual

22 November 2022

Trial Chairperson

Dr Steven David, Peter MacCallum Cancer Centre, VIC

HeSANDA database for clinical trial data

21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

16 April, 2025

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

LATEST NEWS: 15 April 2025 An innovative trial aimed

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer

R2810-ONC-1788/TROG 17.11 – CPOST

ICR-CTSU/2015/15552/TROG 16.03 – CORE

Related Post

Trial data-sharing made easier with HeSANDA initiative

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

TROG 20.03 – AVATAR

A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer

R2810-ONC-1788/TROG 17.11 – CPOST

ICR-CTSU/2015/15552/TROG 16.03 – CORE

Related Post

Trial data-sharing made easier with HeSANDA initiative

Mark Hughes Foundation grant for innovative SMART trial into brain metastases